Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Clarivate sale of Life Sciences & Healthcare segment to Altaris
We are advising Clarivate on the transaction
Alebund Pharmaceuticals HK$1.28 billion IPO
We advised Alebund Pharmaceuticals on its IPO and HKEX listing
Talawar Therapeutics $225 million PIPE financing and de-SPAC transaction
We advised the placement agents on the transaction
NeoGenomics $316.25 million convertible senior notes offering
We advised the initial purchasers on the offering
SOPHiA GENETICS $57.5 million follow-on offering
We advised SOPHiA GENETICS on the offering
PTC Therapeutics $550 million convertible senior notes offering
We advised the initial purchasers on the offering
TARGAN sale to Merck Animal Health
We are advising TARGAN on the transaction
IDEAYA Biosciences $345 million equity offering
We advised the joint book-running managers and underwriters on the offering
Novanta $300 million private placement
We advised the placement agents on the transaction
GSK $10.6 billion acquisition of Nuvalent
We are advising GSK on the transaction